At Week 52 (SINUS-52), DUPIXENT demonstrated1:
IN NC SCORE
LSM change from a baseline
score of 2.38 (n=35)
-0.21 improvement from a
baseline score of 2.49 with
placebo + INCS (n=44) (LSM
difference vs placebo: -1.13
[95% CI: -1.49, -0.77])1
IN NPS
LSM change from a baseline
score of 5.87 (n=35)
0.03 worsening with
placebo + INCS (n=44) (LSM
change from a baseline
score of 6.06) (LSM
difference vs placebo: -2.57
[95% CI: -3.27, -1.87])1
IN LMK-CT SCORE
LSM change from a baseline
score of 19.71 (n=35)
-0.41 improvement from a
baseline score of 19.07 with
placebo + INCS (n=44) (LSM
difference vs placebo: -6.86
[95% CI: -8.62, -5.10])1
Analysis was not multiplicity controlled; results are descriptive.
27% of patients enrolled in SINUS-52 presented with NSAID-ERD.2
INCS, intranasal corticosteroid; LSM, least squares mean; NC, nasal congestion/obstruction; NPS, nasal polyp score; NSAID-ERD,
nonsteroidal anti-inflammatory drug–exacerbated respiratory disease.Explore the Safety Data
and Study Designs
Dosage and
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.